​

Hims & Hers Health (HIMS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HIMS Stock Forecast

Hims & Hers Health stock forecast is as follows: an average price target of $24.67 (represents a -5.84% downside from HIMS’s last price of $26.20) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

HIMS Price Target

The average price target for Hims & Hers Health (HIMS) is $24.67 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $18.00. This represents a potential -5.84% downside from HIMS's last price of $26.20.

HIMS Analyst Ratings

Buy

According to 16 Wall Street analysts, Hims & Hers Health's rating consensus is 'Buy'. The analyst rating breakdown for HIMS stock is 1 'Strong Buy' (6.25%), 10 'Buy' (62.50%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Hims & Hers Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 02, 2024Maria RippsCanaccord Genuity$38.00$30.8123.34%45.04%
Nov 05, 2024Korinne WolfmeyerPiper Sandler$21.00$20.641.74%-19.85%
Nov 05, 2024Ryan MacDonaldNeedham$28.00$20.9633.59%6.87%
Oct 29, 2024Michael ChernyLeerink Partners$26.00$23.0812.65%-0.76%
Oct 21, 2024Michael ChernyBank of America Securities$25.00$22.1512.87%-4.58%
Oct 14, 2024Michael ChernyBank of America Securities$23.00$19.8216.02%-12.21%
Oct 14, 2024Jailendra SinghTruist Financial$23.00$19.8216.02%-12.21%
Sep 13, 2024Allen LutzBank of America Securities$20.00$15.8226.42%-23.66%
Aug 27, 2024Daniel GrosslightCitigroup$20.00$14.9334.00%-23.66%
Aug 07, 2024Glen SantangeloJefferies$18.00$16.0412.22%-31.30%
Aug 06, 2024George HillDeutsche Bank$23.00$16.8836.26%-12.21%
May 22, 2024Maria RippsCanaccord Genuity$24.00$17.5636.67%-8.40%
May 07, 2024Glen SantangeloJefferies$14.00$12.3513.36%-46.56%
May 07, 2024Jailendra SinghTruist Financial$13.00$12.404.80%-50.38%
May 07, 2024Korinne WolfmeyerPiper Sandler$13.00$12.384.97%-50.38%
May 07, 2024George HillDeutsche Bank$16.00$11.6537.34%-38.93%
Apr 16, 2024Glen SantangeloJefferies$15.00$13.2213.46%-42.75%
Apr 10, 2024Maria RippsCanaccord Genuity$20.00$14.5537.46%-23.66%
Aug 10, 2022Credit Suisse$8.00$6.5721.86%-69.47%
Aug 09, 2022Leerink Partners$5.00$6.71-25.48%-80.92%
May 26, 2022Piper Sandler$6.00$3.5967.13%-77.10%

The latest Hims & Hers Health stock forecast, released on Dec 02, 2024 by Maria Ripps from Canaccord Genuity, set a price target of $38.00, which represents a 23.34% increase from the stock price at the time of the forecast ($30.81), and a 45.04% increase from HIMS last price ($26.20).

Hims & Hers Health Price Target by Period

1M3M12M
# Anlaysts1718
Avg Price Target$38.00$26.29$21.11
Last Closing Price$26.20$26.20$26.20
Upside/Downside45.04%0.34%-19.43%

In the current month, the average price target of Hims & Hers Health stock is $38.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 45.04% increase as opposed to Hims & Hers Health's last price of $26.20. This month's average price target is up 44.54% compared to last quarter, and up 80.01% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024Canaccord GenuityBuyBuyHold
Nov 05, 2024NeedhamBuyBuyHold
Oct 29, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 21, 2024NeedhamUnderperformUnderperformHold
Oct 21, 2024Piper SandlerBuyBuyHold
Oct 14, 2024Bank of America SecuritiesBuyBuyHold
Oct 03, 2024CitigroupNeutralNeutralHold
Sep 13, 2024Sandler O'NeillBuyBuyHold
Sep 13, 2024Sandler O'NeilUnderperformUnderperformHold
Aug 27, 2024CitigroupNeutralNeutralHold
Aug 22, 2024NeedhamBuyInitialise
Aug 07, 2024JefferiesHoldHoldHold
Aug 06, 2024Deutsche BankHoldHoldHold
Aug 06, 2024Sandler O'NeillBuyBuyHold
Aug 06, 2024Sandler O'NeilUnderperformUnderperformHold
Aug 06, 2024Seaport GlobalBuyBuyHold
Jul 11, 2024Cowen & Co.BuyBuyHold
Jul 11, 2024Piper SandlerNeutralNeutralHold
Jun 27, 2024JefferiesHoldHoldHold
Jun 13, 2024Bank of America SecuritiesBuyBuyHold
May 29, 2024Seaport GlobalBuyBuyHold
May 22, 2024Canaccord GenuityBuyBuyHold
May 22, 2024CitigroupBuyNeutralDowngrade
May 20, 2024CitigroupBuyBuyHold
May 14, 2024Bank of America SecuritiesBuyBuyHold
May 07, 2024JefferiesHoldHoldHold
May 07, 2024Seaport GlobalBuyBuyHold
May 07, 2024Piper SandlerNeutralNeutralHold
May 07, 2024Deutsche BankHoldHoldHold
Apr 16, 2024JefferiesBuyHoldDowngrade
Feb 27, 2024Imperial CapitalOutperformUpgrade
Feb 27, 2024GuggenheimBuyBuyHold
Feb 27, 2024Piper SandlerNeutralNeutralHold
Feb 27, 2024CitigroupBuyBuyHold
Feb 09, 2023CFRAStrong BuyUpgrade
Feb 09, 2023JefferiesBuyUpgrade
Nov 08, 2022SVB LeerinkUnderperformMarket PerformUpgrade
Nov 08, 2022Bank of America SecuritiesBuyUpgrade
Oct 18, 2022Sandler O'NeillNeutralDowngrade
Aug 10, 2022Credit SuisseOutperformOutperformHold
Aug 09, 2022SVB LeerinkUnderperformUnderperformHold
May 26, 2022Piper SandlerOverweightOverweightHold
Nov 16, 2021Piper SandlerNeutralUpgrade

Hims & Hers Health's last stock rating was published by Canaccord Genuity on Dec 02, 2024. The company gave HIMS a "Buy" rating, the same as its previous rate.

Hims & Hers Health Financial Forecast

Hims & Hers Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue------------$246.62M$226.70M$207.91M$190.77M$167.20M$144.84M$113.56M$101.31M$84.70M$74.17M$60.69M$52.31M$41.47M
Avg Forecast$541.61M$527.34M$521.97M$513.71M$531.71M$511.27M$518.13M$496.13M$469.33M$382.20M$304.66M$270.37M$246.47M$220.08M$204.95M$179.08M$161.17M$130.32M$103.89M$91.23M$76.79M$70.53M$56.49M$48.71M$37.00M
High Forecast$564.66M$549.79M$544.19M$535.58M$554.34M$533.03M$540.18M$518.35M$474.44M$384.05M$305.76M$270.37M$247.45M$220.08M$213.68M$186.70M$168.03M$130.32M$103.89M$91.23M$76.79M$70.53M$56.49M$48.71M$37.00M
Low Forecast$504.72M$491.43M$486.42M$478.72M$495.50M$476.45M$482.84M$457.25M$466.26M$380.34M$303.56M$270.37M$245.14M$220.08M$190.99M$166.88M$150.20M$130.32M$103.89M$91.23M$76.79M$70.53M$56.49M$48.71M$37.00M
# Analysts3333444694347563222234566
Surprise %------------1.00%1.03%1.01%1.07%1.04%1.11%1.09%1.11%1.10%1.05%1.07%1.07%1.12%

Hims & Hers Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $270.37M, with a low forecast of $270.37M, and a high forecast of $270.37M. HIMS's average Quarter revenue forecast represents a 9.63% increase compared to the company's last Quarter revenue of $246.62M (Dec 23).

Hims & Hers Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts3333444694347563222234566
EBITDA------------$-400.00K$-8.55M$-9.24M$-9.15M$-11.61M$-18.53M$-18.49M$-15.62M$-29.62M$-17.57M$-8.61M$-50.92M$-4.84M
Avg Forecast$-166.83M$-162.43M$-160.78M$-158.23M$-163.78M$-157.48M$-159.59M$-152.82M$-144.56M$-117.72M$-93.84M$-81.48M$-75.92M$-67.79M$-63.13M$-64.41M$-27.84M$-40.13M$-17.85M$-28.09M$-23.65M$-21.72M$-17.39M$-50.92M$-11.39M
High Forecast$-155.46M$-151.37M$-149.83M$-147.46M$-152.62M$-146.76M$-148.73M$-140.84M$-143.62M$-117.15M$-93.50M$-65.19M$-75.51M$-67.79M$-58.83M$-51.53M$-22.27M$-40.13M$-14.28M$-28.09M$-23.65M$-21.72M$-17.39M$-40.74M$-11.39M
Low Forecast$-173.93M$-169.35M$-167.62M$-164.97M$-170.75M$-164.19M$-166.39M$-159.66M$-146.14M$-118.30M$-94.18M$-97.78M$-76.22M$-67.79M$-65.82M$-77.30M$-33.40M$-40.13M$-21.42M$-28.09M$-23.65M$-21.72M$-17.39M$-61.10M$-11.39M
Surprise %------------0.01%0.13%0.15%0.14%0.42%0.46%1.04%0.56%1.25%0.81%0.50%1.00%0.42%

undefined analysts predict HIMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Hims & Hers Health's previous annual EBITDA (undefined) of $NaN.

Hims & Hers Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts3333444694347563222234566
Net Income------------$3.15M$-7.57M$-7.16M$-10.07M$-10.91M$-18.84M$-19.68M$-16.25M$-31.16M$-15.94M$-9.15M$-51.40M$-5.23M
Avg Forecast$39.63M$42.93M$41.86M$42.26M$54.07M$49.36M$44.66M$38.39M$41.76M$26.14M$10.48M$-82.26M$-5.25M$-8.39M$-11.40M$-65.03M$-29.29M$-23.81M$-19.68M$-19.52M$-20.85M$-18.82M$-19.51M$-51.40M$-37.72M
High Forecast$41.82M$45.31M$44.17M$44.60M$57.06M$52.10M$47.13M$70.88M$55.68M$27.59M$10.78M$-65.81M$-2.62M$-7.65M$-10.39M$-52.02M$-23.43M$-23.81M$-15.74M$-19.52M$-20.85M$-18.82M$-19.51M$-41.12M$-37.72M
Low Forecast$36.12M$39.13M$38.15M$38.52M$49.28M$44.99M$40.71M$23.63M$31.32M$23.83M$10.18M$-98.71M$-10.49M$-8.85M$-12.03M$-78.03M$-35.14M$-23.81M$-23.61M$-19.52M$-20.85M$-18.82M$-19.51M$-61.68M$-37.72M
Surprise %-------------0.60%0.90%0.63%0.15%0.37%0.79%1.00%0.83%1.49%0.85%0.47%1.00%0.14%

Hims & Hers Health's average Quarter net income forecast for Mar 24 is $-82.26M, with a range of $-98.71M to $-65.81M. HIMS's average Quarter net income forecast represents a -2713.85% decrease compared to the company's last Quarter net income of $3.15M (Dec 23).

Hims & Hers Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts3333444694347563222234566
SG&A------------$158.21M$151.98M$138.36M$127.76M$113.11M$126.46M$107.37M$91.67M$83.66M$82.53M$64.68M$88.66M$36.52M
Avg Forecast$536.47M$522.34M$517.02M$508.84M$526.67M$506.42M$513.21M$491.42M$464.88M$378.57M$301.77M$141.87M$244.13M$217.99M$203.01M$112.15M$78.63M$130.47M$46.88M$91.34M$76.88M$70.61M$56.55M$48.77M$37.04M
High Forecast$559.31M$544.58M$539.03M$530.50M$549.09M$527.98M$535.06M$513.44M$469.94M$380.41M$302.86M$170.24M$245.10M$217.99M$211.65M$134.58M$94.36M$130.47M$56.25M$91.34M$76.88M$70.61M$56.55M$48.77M$37.04M
Low Forecast$499.93M$486.77M$481.81M$474.19M$490.80M$471.93M$478.26M$452.92M$461.84M$376.73M$300.68M$113.50M$242.82M$217.99M$189.18M$89.72M$62.91M$130.47M$37.50M$91.34M$76.88M$70.61M$56.55M$48.77M$37.04M
Surprise %------------0.65%0.70%0.68%1.14%1.44%0.97%2.29%1.00%1.09%1.17%1.14%1.82%0.99%

Hims & Hers Health's average Quarter SG&A projection for Mar 24 is $141.87M, based on 4 Wall Street analysts, with a range of $113.50M to $170.24M. The forecast indicates a -10.33% fall compared to HIMS last annual SG&A of $158.21M (Dec 23).

Hims & Hers Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts3333444694347563222234566
EPS-------------$-0.04$-0.03$-0.05$-0.05$-0.09$-0.10$-0.08$-0.15$-0.08$-0.05$-0.34$-0.07
Avg Forecast$0.17$0.18$0.18$0.18$0.23$0.21$0.19$0.16$0.18$0.11$0.04$0.01$-0.02$-0.04$-0.05$-0.02$-0.06$-0.10$-0.08$-0.08$-0.09$-0.08$-0.08$-0.11$-0.16
High Forecast$0.18$0.19$0.19$0.19$0.24$0.22$0.20$0.30$0.24$0.12$0.05$0.01$-0.01$-0.03$-0.04$-0.02$-0.05$-0.10$-0.08$-0.08$-0.09$-0.08$-0.08$-0.11$-0.16
Low Forecast$0.15$0.17$0.16$0.16$0.21$0.19$0.17$0.10$0.13$0.10$0.04$0.01$-0.04$-0.04$-0.05$-0.02$-0.06$-0.10$-0.08$-0.08$-0.09$-0.08$-0.08$-0.11$-0.16
Surprise %-------------1.01%0.71%2.36%0.90%0.91%1.19%0.96%1.69%1.00%0.60%3.14%0.44%

According to undefined Wall Street analysts, Hims & Hers Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HIMS previous annual EPS of $NaN (undefined).

Hims & Hers Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GROVGrove Collaborative$1.39$150.0010691.37%Buy
COTYCoty$7.32$12.5070.77%Buy
ELEstée Lauder Companies$78.18$112.8344.32%Hold
ELFe.l.f. Beauty$134.89$170.1726.15%Buy
IPARInter Parfums$133.41$163.5022.55%Buy
CLColgate-Palmolive Company$93.49$108.6716.24%Buy
KVUEKenvue$22.04$24.7512.30%Buy
NWLNewell Brands$10.50$11.7011.43%Buy
PGProcter & Gamble Company$170.33$173.922.11%Buy
HNSTHonest Company$7.09$7.00-1.27%Buy
HIMSHims & Hers Health$31.12$24.67-20.73%Buy

HIMS Forecast FAQ

Is Hims & Hers Health a good buy?

Yes, according to 16 Wall Street analysts, Hims & Hers Health (HIMS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 10 'Buy' recommendations, accounting for 68.75% of HIMS's total ratings.

What is HIMS's price target?

Hims & Hers Health (HIMS) average price target is $24.67 with a range of $18 to $38, implying a -5.84% from its last price of $26.2. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Hims & Hers Health stock go up soon?

According to Wall Street analysts' prediction for HIMS stock, the company can go down by -5.84% (from the last price of $26.2 to the average price target of $24.67), up by 45.04% based on the highest stock price target, and down by -31.30% based on the lowest stock price target.

Can Hims & Hers Health stock reach $40?

HIMS's average twelve months analyst stock price target of $24.67 does not support the claim that Hims & Hers Health can reach $40 in the near future.

What is Hims & Hers Health's current price target trend?

1 Wall Street analyst forecast a $38 price target for Hims & Hers Health (HIMS) this month, up 45.04% from its last price of $26.2. Compared to the last 3 and 12 months, the average price target increased by 0.34% and decreased by -19.43%, respectively.

What are Hims & Hers Health's analysts' financial forecasts?

Hims & Hers Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.06B (high $2.15B, low $1.91B), average EBITDA is $-634M (high $-589M, low $-661M), average net income is $186.49M (high $227.17M, low $158.61M), average SG&A $2.04B (high $2.13B, low $1.89B), and average EPS is $0.793 (high $0.966, low $0.675). HIMS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.1B (high $2.19B, low $1.96B), average EBITDA is $-648M (high $-604M, low $-676M), average net income is $166.68M (high $175.9M, low $151.92M), average SG&A $2.08B (high $2.17B, low $1.94B), and average EPS is $0.709 (high $0.748, low $0.646).

Did the HIMS's actual financial results beat the analysts' financial forecasts?

Based on Hims & Hers Health's last annual report (Dec 2023), the company's revenue was $872M, beating the average analysts forecast of $850.58M by 2.52%. Apple's EBITDA was $-29.453M, missing the average prediction of $-271M by -89.14%. The company's net income was $-23.546M, missing the average estimation of $-90.056M by -73.85%. Apple's SG&A was $576.32M, missing the average forecast of $777.28M by -25.85%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.127 by -99.92%. In terms of the last quarterly report (Dec 2023), Hims & Hers Health's revenue was $246.62M, beating the average analysts' forecast of $246.47M by 0.06%. The company's EBITDA was $-400K, missing the average prediction of $-75.917M by -99.47%. Hims & Hers Health's net income was $3.15M, missing the average estimation of $-5.246M by -159.99%. The company's SG&A was $158.21M, missing the average forecast of $244.13M by -35.19%. Lastly, the company's EPS was $0, missing the average prediction of $-0.0223 by -100.00%